source
- AbbVie beats Q3 expectations, lifts full-year EPS outlook as immunology and neuroscience drive growthAbbVie reported third-quarter results that exceeded analysts' sales and earnings per share forecasts. The company posted $17.4 billion in revenue, driven largely by its immunology franchise which…
- Alnylam shares tumble 25% as analysts flag uncertainties in its transthyretin franchiseAlnylam Therapeutics saw its stock fall about a quarter on Thursday, closing near $174 after analysts highlighted a trio of uncertainties surrounding its transthyretin (TTR) franchise. The TTR fra…